Story perspectives

FDA Approves First Self-Administered Nasal Diuretic

9/19/2025

49 8

Summary

Story summary

The FDA approved Corstasis Therapeutics’ Enbumyst, the first self-administered nasal diuretic for adult edema treatment.
Enbumyst will be available in the U.S. by Q4 2025 and uses Aptar Pharma’s Unidose System.
Clinical studies indicate Enbumyst absorbs 33% faster than oral bumetanide.
Common side effects include hypovolemia (4.8%) and headache (3%).
Nasal delivery systems are increasingly used for therapies, showing promise in neurological and metabolic disorders.

1 of 1

Story summary

The FDA approved Corstasis Therapeutics’ Enbumyst, the first self-administered nasal diuretic for adult edema treatment.
Enbumyst will be available in the U.S. by Q4 2025 and uses Aptar Pharma’s Unidose System.
Clinical studies indicate Enbumyst absorbs 33% faster than oral bumetanide.
Common side effects include hypovolemia (4.8%) and headache (3%).
Nasal delivery systems are increasingly used for therapies, showing promise in neurological and metabolic disorders.